Home page > News
 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
ARCHIVE NEWS
New record for the Chiesi Group, which is confirmed top Italian pharmaceutical company for number of patents filed
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
The Chiesi Group is on Twitter!
Chiesi Group: performance is up in 2020
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
Chiesi Group receives Diversity Leaders Award 2021
World Prematurity Day: Chiesi is at the forefront for preterm babies
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
Chiesi USA, Inc. announces FDA approval of Bronchitol® (mannitol) inhalation powder
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
Regeneration 20|3, the first global meeting to launch the program is in Parma on October 15 and 16.
Italy for Climate: Chiesi at the forefront for the future of Italy
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group Announces Establishment of New Global Rare Diseases Division